Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 10/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | G6PD | P11413 | 1/20 | 0.57 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.57 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250475 | 1.00 | DHODH (0.82) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL3250476 | 1.00 | DHODH (0.82) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL21067830 | 0.90 | DHODH (1.00) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL12588738 | 0.89 | DHODH (0.67) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL8810371 | 0.88 | DHODH (0.74) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL9079477 | 0.88 | DHODH (0.74) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL9080958 | 0.88 | DHODH (0.74) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL8810121 | 0.88 | DHODH (0.74) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL12202668 | 0.86 | DHODH (0.72) | DHODHMEN1KMT2AG6PDCACNA1B | |
| SCHEMBL7517127 | 0.86 | DHODH (0.68) | DHODHMEN1KMT2AG6PDCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10876096-B2 | Cell culture medium for enhanced hepatocyte function | CORNING INCORPORATED (US) | 2020-12-29 | — | — | US | disclosed |
| EP-2925858-B1 | CELL CULTURE MEDIUM FOR ENHANCED HEPATOCYTE FUNCTION | CORNING INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20150291932-A1 | CELL CULTURE MEDIUM FOR ENHANCED HEPATOCYTE FUNCTION | DISCOVERY LIFE SCIENCES, LLC | 2015-10-15 | — | — | US | disclosed |
| US-20060167090-A1 | BTK inhibitors | PARKER HUGHES INSTITUTE (US) | 2006-07-27 | — | — | US | disclosed |
| US-6864286-B2 | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use | PARKER HUGHES INSTITUTE (US) | 2005-03-08 | — | — | US | disclosed |
| US-6753348-B2 | BRUTON'S TYROSINE KINASE; CONTACTING MAST CELLS WITH A LEUKOTRIENE ALTERING AMOUNT OF A LEFLUNOMIDE ANALOG | PARKER HUGHES INSTITUTE | 2004-06-22 | — | — | US | disclosed |
| EP-1071658-B1 | BTK INHIBITORS AND METHODS FOR THEIR IDENTIFICATION AND USE | PARKER HUGHES INST (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030144351-A1 | BTK inhibitors and methods for their identification and use | PARKER HUGHES INSTITUTE (US) | 2003-07-31 | — | — | US | disclosed |
| US-20020107284-A1 | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use | PARKER HUGHES INSTITUTE (US) | 2002-08-08 | — | — | US | disclosed |
| US-6365626-B1 | LEFLUNOMIDE METABOLITE ANALOGS FOR TREATING IMPROPER PLATELET AGGREGATION; LEUKEMIA; LYMPHOMAS | PARKER HUGHES INSTITUTE | 2002-04-02 | — | — | US | disclosed |
| US-6355678-B1 | ANTICANCER AGENTS; ENZYME INHIBITOR | PARKER HUGHES INSTITUTE | 2002-03-12 | — | — | US | disclosed |
| US-6303652-B1 | CONTACTING BRUTON'S TYROSINE KINASE (BTK) OR A CELL THAT EXPRESSES BTK WITH AMIDE COMPOUND TO INHIBIT BTK ACTIVITY | HUGHES INSTITUTE | 2001-10-16 | — | — | US | disclosed |
| US-6221900-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK). | HUGHES INSTITUTE | 2001-04-24 | — | — | US | disclosed |
| EP-1071658-A2 | BTK INHIBITORS AND METHODS FOR THEIR IDENTIFICATION AND USE | Parker Hughes Institute (US) | 2001-01-31 | — | — | EP | disclosed |
| US-6160010-A | BTK inhibitors and methods for their identification and use | PARKER HUGHES INSTITUTE (US) | 2000-12-12 | — | — | US | disclosed |
| WO-1999054286-A2 | BTK INHIBITORS AND METHODS FOR THEIR IDENTIFICATION AND USE | PARKER HUGHES INSTITUTE (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144351-A1 | BTK inhibitors and methods for their identification and use | BTK, SYK, LYN | DHODH 2300/4885MEN1 3955/4885KMT2A 905/4885 |
| US-20020107284-A1 | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use | EGFR, ERBB2, ERBB3 | DHODH 2455/4885MEN1 3875/4885KMT2A 3133/4885 |
| US-20060167090-A1 | BTK inhibitors | BTK, SYK, LYN | DHODH 2219/4885MEN1 3599/4885KMT2A 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.